WO1997035969A3 - Peptide ligands of the urokinase receptor - Google Patents

Peptide ligands of the urokinase receptor Download PDF

Info

Publication number
WO1997035969A3
WO1997035969A3 PCT/US1997/005199 US9705199W WO9735969A3 WO 1997035969 A3 WO1997035969 A3 WO 1997035969A3 US 9705199 W US9705199 W US 9705199W WO 9735969 A3 WO9735969 A3 WO 9735969A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
upar
binding
peptide ligands
urokinase receptor
Prior art date
Application number
PCT/US1997/005199
Other languages
French (fr)
Other versions
WO1997035969A9 (en
WO1997035969A2 (en
Inventor
Steven Rosenberg
Michael Doyle
Harold A Chapman
Original Assignee
Chiron Corp
Brigham & Womens Hospital
Steven Rosenberg
Michael Doyle
Chapman Harol A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Brigham & Womens Hospital, Steven Rosenberg, Michael Doyle, Chapman Harol A filed Critical Chiron Corp
Priority to JP53466697A priority Critical patent/JP4088344B2/en
Priority to US09/155,260 priority patent/US6794358B1/en
Priority to EP97917723A priority patent/EP0906419A2/en
Priority to AU25978/97A priority patent/AU2597897A/en
Publication of WO1997035969A2 publication Critical patent/WO1997035969A2/en
Publication of WO1997035969A3 publication Critical patent/WO1997035969A3/en
Publication of WO1997035969A9 publication Critical patent/WO1997035969A9/en
Priority to US10/821,544 priority patent/US7094752B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.
PCT/US1997/005199 1996-03-28 1997-03-28 Peptide ligands of the urokinase receptor WO1997035969A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP53466697A JP4088344B2 (en) 1996-03-28 1997-03-28 Peptide ligand of urokinase receptor
US09/155,260 US6794358B1 (en) 1997-03-28 1997-03-28 Peptide ligands of the urokinase receptor
EP97917723A EP0906419A2 (en) 1996-03-28 1997-03-28 Peptide ligands of the urokinase receptor
AU25978/97A AU2597897A (en) 1996-03-28 1997-03-28 Peptide ligands of the urokinase receptor
US10/821,544 US7094752B2 (en) 1997-03-28 2004-04-09 Peptide ligands of the urokinase receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62336196A 1996-03-28 1996-03-28
US08/623,361 1996-03-28

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/155,260 A-371-Of-International US6794358B1 (en) 1997-03-28 1997-03-28 Peptide ligands of the urokinase receptor
US09155260 A-371-Of-International 1997-03-28
US10/821,544 Division US7094752B2 (en) 1997-03-28 2004-04-09 Peptide ligands of the urokinase receptor

Publications (3)

Publication Number Publication Date
WO1997035969A2 WO1997035969A2 (en) 1997-10-02
WO1997035969A3 true WO1997035969A3 (en) 1997-11-06
WO1997035969A9 WO1997035969A9 (en) 1997-12-31

Family

ID=24497795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005199 WO1997035969A2 (en) 1996-03-28 1997-03-28 Peptide ligands of the urokinase receptor

Country Status (4)

Country Link
EP (1) EP0906419A2 (en)
JP (2) JP4088344B2 (en)
AU (1) AU2597897A (en)
WO (1) WO1997035969A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR020101A1 (en) * 1998-07-01 2002-04-10 Cancerforskingsfonden Af 1989 A PEPTIDE ANTAGONIST OF THE HUMAN UROQUINASE RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING HIM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHODOPARA TO SELECT AN ADEQUATE PEPTIDE ANTAGONIST.
EP0982036A1 (en) * 1998-08-28 2000-03-01 Wilex Biotechnology GmbH Modulation of Beta2 -integrin-mediated cell adhesion
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2388341T3 (en) 1998-10-23 2012-10-11 Kirin-Amgen Inc. Dimeric thrombopoietin mimetic peptides that bind to the MPL receptor and that have thrombopoietic activity
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
JP2003530871A (en) * 2000-04-21 2003-10-21 アムジエン・インコーポレーテツド Integrin / adhesion factor antagonist
CA2408812A1 (en) * 2000-05-09 2001-11-15 Dgi Biotechnologies, Inc. Methods of identifying the activity of gene products
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
JP2008505928A (en) 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド Therapeutic peptide
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
BR112013016107A2 (en) * 2010-12-22 2017-04-04 Ifom Fond Inst Firc Di Oncologia Molecolare dimeric molecule, cancer treatment method, pharmaceutical composition and kit for the diagnosis of an upar-mediated pathology or tumor
CA2842281A1 (en) 2011-08-05 2013-02-14 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
WO2019165105A1 (en) * 2018-02-26 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOYLE M V ET AL: "The discovery of novel urokinase receptor ligands by bacteriophage display and combinatorial chemistry", FIBRINOLYSIS, 10 (SUPPL. 3). 1996. 21., XP002040489 *
GOODSON RJ ET AL: "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.", PROC NATL ACAD SCI U S A, JUL 19 1994, 91 (15) P7129-33, UNITED STATES, XP000574761 *
STRATTON-THOMAS JR ET AL: "Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain.", PROTEIN ENG, MAY 1995, 8 (5) P463-70, ENGLAND, XP000574760 *
WALTZ DA ET AL: "Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.", J BIOL CHEM, MAY 20 1994, 269 (20) P14746-50, UNITED STATES, XP002040491 *
WEI Y ET AL: "Identification of the urokinase receptor as an adhesion receptor for vitronectin.", J BIOL CHEM, DEC 23 1994, 269 (51) P32380-8, UNITED STATES, XP002040490 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules

Also Published As

Publication number Publication date
EP0906419A2 (en) 1999-04-07
JP2000509968A (en) 2000-08-08
JP4088344B2 (en) 2008-05-21
AU2597897A (en) 1997-10-17
JP2008109934A (en) 2008-05-15
WO1997035969A2 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
WO1997035969A3 (en) Peptide ligands of the urokinase receptor
EP1137658A4 (en) METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
DE69533923D1 (en) CYTOKININ-DESIGNED LERK-5
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
IL100731A0 (en) Mixed specificity fusion protein and pharmaceutical composition containing it
DE1007654T1 (en) In vitro peptide or protein expression bank
MXPA02012743A (en) Il-17 molecules and uses thereof.
DE69434299T2 (en) Thiol-derivatized nucleosides and oligonucleosides
EP0851870A4 (en) Colon cell and colon cancer cell associated nucleic acid molecules, protein and peptides
WO2004020595A8 (en) Novel human polypeptides encoded by polynucleotides
ATE279203T1 (en) USE OF SUBSTRATE SUBTRACTION LIBRARIES TO DIFFERENTIATE ENZYME SPECIFICITIES
WO2001031335A3 (en) Cell proliferation diagnosis and screening for modulators
AU1207301A (en) Stabilized proteins
WO2004066958A3 (en) Caspase-9:bir3 domain of xiap complexes and methods of use
AU8881201A (en) Tnf receptor-like molecules and uses thereof
CA2302147A1 (en) Methods for protein screening
DE69616303D1 (en) O-MALONYLTYROSYL COMPOUNDS, PEPTIDES CONTAINING O-MALONYLTYROSYL COMPOUNDS AND THEIR USE
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
MX9602557A (en) Proteins from mammalian liver and their use in oncology.
TR199800517A2 (en) Hémanize anti-hémen fas antikor.
MXPA03004578A (en) Novel polypeptides involved in immune response.
AU2003270010A8 (en) Transferrin fusion protein libraries
ATE364706T1 (en) NUCLEOTIDE AND PROTEIN SEQUENCE OF MAMMASTATIN AND METHODS OF APPLICATION
ATE344327T1 (en) REGULATION OF THE EXCLUSION OF PROTEINS
GB9811221D0 (en) Bacterial-pheromones and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA IL JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09155260

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997917723

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997917723

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997917723

Country of ref document: EP